Dr Cappuzzo Publiredac Crossword

12345678
Across
  1. 1. In second line mNSCLC at this point ... is an important treatment goal
  2. 4. EGFR mutations present an important target that should be ... in any patient before starting therapy
  3. 5. Third generation TKI's will potentially have their place in ... tumors
  4. 6. MDPL3280A is a Roche compound in development targetting ...
  5. 8. Of which drug Dr Cappuzzo noted that it's major advantage may be it's really really good tolerability?
Down
  1. 2. Rash affects about 66-74% of TKI treated pts among studies, but gefitinib produces more ...
  2. 3. The available therapies for NSCLC patients who have no identifiable biomarkers have ... and only modest efficacy
  3. 7. Despite promising pre-clinical data, afatinib was not shown to be effective in patients with ... restistance
  4. 8. A major toxicity seen with ... is diarrhea